Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT)
| Autor: | Norikazu Hiura, Masahiko Fukatani, Akiyoshi Kakutani, Kazushi Yukiiri, Shigenobu Bando, Yamato Fukuda, Katsuhito Yamamoto, Yuichiro Takagi, Akiyoshi Nishikado, Noriyoshi Kaname, Yutaka Nakaya, Shuntaro Ikeda |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty 030204 cardiovascular system & hematology Young Adult 03 medical and health sciences 0302 clinical medicine Japan Rivaroxaban Risk Factors Retrospective survey Thromboembolism Internal medicine Atrial Fibrillation Humans Medicine Registries Young adult Stroke Aged Retrospective Studies Aged 80 and over business.industry Incidence Incidence (epidemiology) Retrospective cohort study Atrial fibrillation Middle Aged medicine.disease humanities Treatment Outcome Stroke prevention Cardiology Physical therapy Female Cardiology and Cardiovascular Medicine business Intracranial Hemorrhages 030217 neurology & neurosurgery Factor Xa Inhibitors medicine.drug |
| Zdroj: | Journal of Cardiology. 71:197-201 |
| ISSN: | 0914-5087 |
| DOI: | 10.1016/j.jjcc.2017.08.005 |
| Popis: | The Shikoku Rivaroxaban Registry Trial (SRRT) is a retrospective survey of the use of rivaroxaban for stroke prevention in elderly patients in Shikoku, Japan.The SRRT enrolled 1339 patients from 8 hospitals. Patients were divided into two groups according to their age, the extreme elderly group (453 patients aged ≧80 years) and the control group (886 patients aged80 years).In the extreme elderly group, 41.5% of the patients had low body weight (50kg) and 65.1% had abnormal renal function (creatinine clearance50ml/min). The mean CHADSThese results suggest that rivaroxaban is effective and safe in extreme elderly patients with atrial fibrillation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect